Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$0.42 - $0.86 $934,374 - $1.91 Million
-2,224,700 Reduced 67.65%
1,063,769 $861,000
Q2 2023

Aug 14, 2023

BUY
$0.71 - $1.97 $522,219 - $1.45 Million
735,520 Added 28.81%
3,288,469 $2.89 Million
Q1 2023

May 15, 2023

SELL
$0.72 - $1.03 $404,509 - $578,673
-561,819 Reduced 18.04%
2,552,949 $1.89 Million
Q4 2022

Feb 14, 2023

SELL
$0.73 - $14.6 $1.06 Million - $21.1 Million
-1,447,480 Reduced 31.73%
3,114,768 $2.52 Million
Q2 2022

Aug 15, 2022

SELL
$1.33 - $2.31 $98,952 - $171,864
-74,400 Reduced 1.6%
4,562,248 $7.44 Million
Q1 2022

May 16, 2022

BUY
$1.26 - $2.52 $2.84 Million - $5.67 Million
2,251,512 Added 94.4%
4,636,648 $10.6 Million
Q4 2021

Feb 14, 2022

BUY
$2.33 - $5.94 $1.26 Million - $3.21 Million
540,831 Added 29.32%
2,385,136 $5.56 Million
Q3 2021

Nov 15, 2021

SELL
$5.89 - $9.35 $70,091 - $111,265
-11,900 Reduced 0.64%
1,844,305 $10.9 Million
Q2 2021

Aug 16, 2021

BUY
$9.16 - $19.51 $121,855 - $259,541
13,303 Added 0.72%
1,856,205 $17 Million
Q3 2020

Nov 16, 2020

SELL
$8.59 - $11.89 $152,111 - $210,548
-17,708 Reduced 0.95%
1,842,902 $17.5 Million
Q2 2020

Aug 14, 2020

SELL
$7.23 - $12.1 $13,737 - $22,990
-1,900 Reduced 0.1%
1,860,610 $21.6 Million
Q1 2020

May 15, 2020

SELL
$5.9 - $13.8 $177,064 - $414,151
-30,011 Reduced 1.59%
1,862,510 $15.4 Million
Q4 2019

Feb 14, 2020

SELL
$6.51 - $12.23 $33,852 - $63,596
-5,200 Reduced 0.27%
1,892,521 $23.1 Million
Q3 2019

Nov 14, 2019

BUY
$6.45 - $8.44 $37,680 - $49,306
5,842 Added 0.31%
1,897,721 $14.2 Million
Q2 2019

Aug 14, 2019

BUY
$6.16 - $14.15 $11.7 Million - $26.8 Million
1,891,879 New
1,891,879 $12.7 Million

Others Institutions Holding HOOK

About HOOKIPA Pharma Inc.


  • Ticker HOOK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,654,500
  • Market Cap $98.7M
  • Description
  • HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transpl...
More about HOOK
Track This Portfolio

Track Redmile Group, LLC Portfolio

Follow Redmile Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redmile Group, LLC with notifications on news.